
Thymosin Alpha-1 + LL-37 — immune resilience.
An immune protocol pairing Thymosin Alpha-1, which modulates T-cell activity and adaptive immunity, with LL-37, the human cathelicidin antimicrobial peptide. Together they support a coordinated immune response and antimicrobial defense.
Who it's for: Adults focused on immune resilience and longevity, or managing frequent infections or chronic inflammatory burden.
IMMUNE GUARD pairs 2 compounds:
Thymosin Alpha-1 (thymic peptide)
Naturally occurring thymic peptide that modulates T-cell activity and dendritic-cell function. Used internationally for immune support and holds FDA orphan-drug status for certain indications.
Used for
LL-37 (human cathelicidin)
The human cathelicidin-derived antimicrobial peptide, with direct activity against bacteria, viruses, and fungi plus immunomodulatory signaling that supports wound healing.
Used for
The following reflects areas of interest commonly reported by members and studied in the clinical literature. Results depend on individual health status, labs, and physician-directed care. Nothing below constitutes a treatment claim.
Thymosin Alpha-1 organizes the adaptive immune response — supporting T-cell and NK-cell activity and antiviral defense.
LL-37 provides broad-spectrum antimicrobial activity while supporting tissue repair.
Together the pair supports immune resilience and longevity, modulating rather than overstimulating immune function.
IMMUNE GUARD is prescribed and monitored against labs. The Halftime Baseline panel ($249, separate onboarding deliverable) covers the relevant markers below.
IMMUNE GUARD is most commonly chosen by members whose primary intent is one of:
Available at every tier
The Halftime Baseline lab panel ($249) is a separate onboarding deliverable, available at any tier.
Join the waitlistLaunching July 1, 2026
All prescriptions require physician evaluation. Compounded medications are not FDA-approved. Individual results vary. This is not medical advice.